MARKET

HOLX

HOLX

Hologic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

70.92
+2.26
+3.29%
After Hours: 70.92 0 0.00% 16:00 10/27 EDT
OPEN
68.41
PREV CLOSE
68.66
HIGH
71.07
LOW
68.41
VOLUME
2.06M
TURNOVER
--
52 WEEK HIGH
73.63
52 WEEK LOW
26.49
MARKET CAP
18.37B
P/E (TTM)
38.04
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Were Hedge Funds Right About Piling Into Hologic, Inc. (HOLX)?
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out […]
Insider Monkey · 17h ago
Hologic Launches 3DQuorum Imaging Technology, Powered by Genius AI, in Europe
Hologic Launches 3DQuorum™ Imaging Technology, Powered by Genius AI™, in Europe
Business Wire · 1d ago
Hologic Reports Commercial Availability In Europe Of Its 3DQuorum Imaging Technology
Hologic, Inc. (NASDAQ:HOLX) today announced the commercial availability in Europe of its 3DQuorum™ Imaging Technology, Powered by Genius AI™. The innovation was designed to help improve mammography efficiency
Benzinga · 1d ago
Braveheart Resources Grants Options
Newsfile · 4d ago
Braveheart Resources and Cadillac Ventures Enter Into Definitive Agreement for Purchase and Sale of Thierry Mine Project
Calgary, Alberta and Toronto, Ontario--(Newsfile Corp. - October 21, 2020) - Braveheart Resources Inc. (TSXV: BHT) (OTCQB: RIINF) ("Braveheart") and Cadillac Ventures Inc. (TSXV: CDC) (OTC: CADIF) ("Cadillac") are pleased to announce that they have entered into a definitive share purchase agreement (the "Definitive Agreement") with respect to the previously announced (see press release of August 18, 2020) purchase by Braveheart of a 100% interest in the Thierry Mine Project (the "Thierry Project") ...
Newsfile · 6d ago
Rally in Covid-Testing Stocks Here to Stay in Virus Resurgence
(Bloomberg) -- Firms that provide Covid-19 testing capabilities have skyrocketed this year and there may be more room for their shares to rally.A new wave of virus cases in the U.S. and Europe signal an insatiable need for more tests to diagnose the disease that currently has no known cure and a vaccine that’s only expected to be rolled out next year at the very earliest. That means companies that make and operate kits, like Quest Diagnostics Inc. and Hologic Inc., should see steady flows of income as patients line up to get tested, money managers and Wall Street analysts say.As the industry soars near record levels -- up 68% from a March bottom -- it’s still cheaper relative to the broader S&P 500 Index than it’s been in recent years. That means a trend of promising earnings could provide a boost this year and well into 2022.“There’s a very positive trend out there for investors because Covid is going to be here for a while -- there is no quick fix,” BNP Paribas Asset Management portfolio manager Christian Fay said by telephone.The iShares U.S. Medical Devices ETF, known by its ticker IHI, peeled off a record Monday as testmakers and lab companies like Abbott Laboratories and Thermo Fisher Scientific Inc. were hit by a broader market decline. Despite the recent surge, some on Wall Street think investors still aren’t giving these firms proper credit for the billions of dollars in expected sales.Investors are “clearly discounting the durability of the revenue stream” from Covid-19 tests, according to Needham & Co. analyst Stephen Unger. He sees the testing opportunity providing a boost into at least 2022.“Current levels don’t fully represent the recurring nature of tests,” he said in an interview. He also believes these tests will have “extraordinary” returns on investments and high margins.Earnings BoostThe upcoming earnings season could provide a further boost for the industry when Abbott, maker of seven Covid-19 tests in the U.S., and Thermo Fisher kick off quarterly results before the market opens on Oct. 21.For life sciences companies like Hologic, Quidel Corp., and Abbott, Covid-19 testing is “obviously the cherry on top” after record runs, said Fay, whose BNP Paribas Funds Health Care Innovators fund holds all three stocks. He’s optimistic on the outlook for the testing space given expectations for people to get a “flu, Covid, and RSV test on a quick turnaround will lead to more people getting tested more often.”While vaccine developers like Moderna Inc., Pfizer Inc. and its partner BioNTech SE, and AstraZeneca have dominated headlines and seen the largest flows of trading over recent months, some investors are preferring to hedge vaccine bets with investments in the diagnostics sector.“I would play out both ends -- diagnostics and vaccines -- because the ability to test to help people get back to normalcy will be key between now and a rolled-out vaccine,” said Amy Kong, chief investment officer of Barrett Asset Management LLC.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Bloomberg · 10/20 13:15
Braveheart Further Increases Financing Up To $1,500,000
Calgary, Alberta--(Newsfile Corp. - October 19, 2020) - Braveheart Resources Inc. (TSXV: BHT) (OTCQB: RIINF) ("Braveheart" or the "Company") is pleased to announce a further increase in the financing initially announced on September 22, 2020, and subsequently increased on October 13, 2020, from $1,050,000 to $1,500,000 due to additional investor demand. The initial financing of $525,000 was arranged through Palisades Goldcorp Ltd.The financing will consist of up to 20,000,000 units ("Units"), priced at ...
Newsfile · 10/20 00:52
Moody's Outlook for the US medical products and devices industry revised to positive on higher earnings, increased demand
Moody's · 10/17 09:53
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HOLX. Analyze the recent business situations of Hologic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HOLX stock price target is 78.21 with a high estimate of 85.00 and a low estimate of 68.00.
EPS
Institutional Holdings
Institutions: 728
Institutional Holdings: 257.75M
% Owned: 99.52%
Shares Outstanding: 258.99M
TypeInstitutionsShares
Increased
142
19.10M
New
147
7.43M
Decreased
207
22.01M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+1.08%
Healthcare Equipment & Supplies
+0.09%
Key Executives
Chairman/President/Chief Executive Officer/Director
Stephen MacMillan
Chief Financial Officer
Karleen Oberton
Corporate Executive
Sanjay Prabhakaran
Corporate Executive
Kevin Thornal
Corporate Executive
Peter Valenti
Corporate Executive
Jan Verstreken
Senior Vice President/Director of Human Resources
Allison Bebo
General Counsel
John Griffin
Chief Accounting Officer
Benjamin Cohn
Vice President/IR Contact Officer
Michael Watts
Lead Director/Independent Director
Sally Crawford
Independent Director
Charles Dockendorff
Independent Director
Scott Garrett
Independent Director
Ludwig Hantson
Independent Director
Namal Nawana
Independent Director
Christiana Stamoulis
Independent Director
Amy Wendell
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About HOLX
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Hologic, Inc. stock information, including NASDAQ:HOLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HOLX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HOLX stock methods without spending real money on the virtual paper trading platform.